Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 2109 entries
Sorted by: Best Match Show Resources per page
Her-2 targeted therapy: beyond breast cancer and trastuzumab

Science interventions

Flaherty KT.
GSID: rY2pRu-5iagJ
KT Flaherty, MS Brose - Current oncology reports, 2006 - Springer

Her-2 is a validated therapeutic target in breast cancer. The two critical questions that remain regarding Her-2 targeting concern 1) the relevance of Her-2 inhibition in other …

Cite
Flaherty, K. T., & Brose, M. S. (2006). Her-2 targeted therapy: beyond breast cancer and trastuzumab. Current oncology reports, 8(2), 90-95.
Flaherty, Keith T., and Marcia S. Brose. "Her-2 targeted therapy: beyond breast cancer and trastuzumab." Current oncology reports 8.2 (2006): 90-95.
Copy Download .nbib Format: MLA
Rapid tumor necrosis and massive hemorrhage induced by bevacizumab and paclitaxel combination therapy in a case of advanced breast cancer.

OncoTargets and therapy

Ono M, Ito T, Kanai T, Murayama K, Koyama H, Maeno K, Mochizuki Y, Iesato A, Hanamura T, Okada T, Watanabe T, Ito K.
PMID: 24124381
Onco Targets Ther. 2013 Oct 07;6:1393-8. doi: 10.2147/OTT.S51164. eCollection 2013.

Bevacizumab when combined with chemotherapy exerts significant activity against many solid tumors through tumor angiogenesis inhibition; however, it can induce severe side effects. We report the rare case of a 27-year-old premenopausal woman with locally advanced breast cancer that...

Cite
Ono M, Ito T, Kanai T, et al. Rapid tumor necrosis and massive hemorrhage induced by bevacizumab and paclitaxel combination therapy in a case of advanced breast cancer. Onco Targets Ther. 2013;6:1393-8doi: 10.2147/OTT.S51164.
Ono, M., Ito, T., Kanai, T., Murayama, K., Koyama, H., Maeno, K., Mochizuki, Y., Iesato, A., Hanamura, T., Okada, T., Watanabe, T., & Ito, K. (2013). Rapid tumor necrosis and massive hemorrhage induced by bevacizumab and paclitaxel combination therapy in a case of advanced breast cancer. OncoTargets and therapy, 61393-8. https://doi.org/10.2147/OTT.S51164
Ono, Mayu, et al. "Rapid tumor necrosis and massive hemorrhage induced by bevacizumab and paclitaxel combination therapy in a case of advanced breast cancer." OncoTargets and therapy vol. 6 (2013): 1393-8. doi: https://doi.org/10.2147/OTT.S51164
Ono M, Ito T, Kanai T, Murayama K, Koyama H, Maeno K, Mochizuki Y, Iesato A, Hanamura T, Okada T, Watanabe T, Ito K. Rapid tumor necrosis and massive hemorrhage induced by bevacizumab and paclitaxel combination therapy in a case of advanced breast cancer. Onco Targets Ther. 2013 Oct 07;6:1393-8. doi: 10.2147/OTT.S51164. eCollection 2013. PMID: 24124381; PMCID: PMC3794845.
Copy Download .nbib Format: NLM
Cardioprotective Effect of Dexrazoxane in Patients with HER2-Positive Breast Cancer Who Receive Anthracycline Based Adjuvant Chemotherapy Followed by Trastuzumab.

Journal of breast cancer

Kim IH, Lee JE, Youn HJ, Song BJ, Chae BJ.
PMID: 28382098
J Breast Cancer. 2017 Mar;20(1):82-90. doi: 10.4048/jbc.2017.20.1.82. Epub 2017 Mar 24.

PURPOSE: We intended to determine whether dexrazoxane (DZR) is cardioprotective during administration of adjuvant anthracycline-based chemotherapy followed by a 1-year trastuzumab treatment.METHODS: The medical records of 228 patients who underwent surgical resection and received adjuvant chemotherapy with trastuzumab for...

Cite
Kim IH, Lee JE, Youn HJ, et al. Cardioprotective Effect of Dexrazoxane in Patients with HER2-Positive Breast Cancer Who Receive Anthracycline Based Adjuvant Chemotherapy Followed by Trastuzumab. J Breast Cancer. 2017;20(1):82-90doi: 10.4048/jbc.2017.20.1.82.
Kim, I. H., Lee, J. E., Youn, H. J., Song, B. J., & Chae, B. J. (2017). Cardioprotective Effect of Dexrazoxane in Patients with HER2-Positive Breast Cancer Who Receive Anthracycline Based Adjuvant Chemotherapy Followed by Trastuzumab. Journal of breast cancer, 20(1), 82-90. https://doi.org/10.4048/jbc.2017.20.1.82
Kim, In-Ho, et al. "Cardioprotective Effect of Dexrazoxane in Patients with HER2-Positive Breast Cancer Who Receive Anthracycline Based Adjuvant Chemotherapy Followed by Trastuzumab." Journal of breast cancer vol. 20,1 (2017): 82-90. doi: https://doi.org/10.4048/jbc.2017.20.1.82
Kim IH, Lee JE, Youn HJ, Song BJ, Chae BJ. Cardioprotective Effect of Dexrazoxane in Patients with HER2-Positive Breast Cancer Who Receive Anthracycline Based Adjuvant Chemotherapy Followed by Trastuzumab. J Breast Cancer. 2017 Mar;20(1):82-90. doi: 10.4048/jbc.2017.20.1.82. Epub 2017 Mar 24. PMID: 28382098; PMCID: PMC5378583.
Copy Download .nbib Format: NLM
Trastuzumab in Esophagogastric Cancer: HER2-Testing and Treatment Reality outside Clinical Studies in Germany.

Gastroenterology research and practice

Merx K, Barreto Miranda M, Kellermann L, Mahlknecht U, Lange O, Gonnermann M, Hofheinz RD.
PMID: 26941786
Gastroenterol Res Pract. 2016;2016:1028505. doi: 10.1155/2016/1028505. Epub 2016 Jan 28.

We analysed trends over time in palliative first-line chemotherapy in patients with locally advanced or metastatic esophagogastric cancer. Special focus was on frequency and quality of HER2-testing and trends in drug use in combination with trastuzumab. Earlier published data...

Cite
Merx K, Barreto Miranda M, Kellermann L, et al. Trastuzumab in Esophagogastric Cancer: HER2-Testing and Treatment Reality outside Clinical Studies in Germany. Gastroenterol Res Pract. 2016;2016:1028505doi: 10.1155/2016/1028505.
Merx, K., Barreto Miranda, M., Kellermann, L., Mahlknecht, U., Lange, O., Gonnermann, M., & Hofheinz, R. D. (2016). Trastuzumab in Esophagogastric Cancer: HER2-Testing and Treatment Reality outside Clinical Studies in Germany. Gastroenterology research and practice, 20161028505. https://doi.org/10.1155/2016/1028505
Merx, Kirsten, et al. "Trastuzumab in Esophagogastric Cancer: HER2-Testing and Treatment Reality outside Clinical Studies in Germany." Gastroenterology research and practice vol. 2016 (2016): 1028505. doi: https://doi.org/10.1155/2016/1028505
Merx K, Barreto Miranda M, Kellermann L, Mahlknecht U, Lange O, Gonnermann M, Hofheinz RD. Trastuzumab in Esophagogastric Cancer: HER2-Testing and Treatment Reality outside Clinical Studies in Germany. Gastroenterol Res Pract. 2016;2016:1028505. doi: 10.1155/2016/1028505. Epub 2016 Jan 28. PMID: 26941786; PMCID: PMC4749805.
Copy Download .nbib Format: NLM
Erratum to: The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer.

Breast cancer research and treatment

van Ramshorst MS, van der Heiden-van der Loo M, Dackus GM, Linn SC, Sonke GS.
PMID: 27534944
Breast Cancer Res Treat. 2016 Sep;159(2):393. doi: 10.1007/s10549-016-3941-6.

No abstract available.

Cite
van Ramshorst MS, van der Heiden-van der Loo M, Dackus GM, et al. Erratum to: The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer. Breast Cancer Res Treat. 2016;159(2):393doi: 10.1007/s10549-016-3941-6.
van Ramshorst, M. S., van der Heiden-van der Loo, M., Dackus, G. M., Linn, S. C., & Sonke, G. S. (2016). Erratum to: The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer. Breast cancer research and treatment, 159(2), 393. https://doi.org/10.1007/s10549-016-3941-6
van Ramshorst, Mette S, et al. "Erratum to: The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer." Breast cancer research and treatment vol. 159,2 (2016): 393. doi: https://doi.org/10.1007/s10549-016-3941-6
van Ramshorst MS, van der Heiden-van der Loo M, Dackus GM, Linn SC, Sonke GS. Erratum to: The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer. Breast Cancer Res Treat. 2016 Sep;159(2):393. doi: 10.1007/s10549-016-3941-6. PMID: 27534944.
Copy Download .nbib Format: NLM
The socio-economical impact of intravenous (IV) versus subcutaneous (SC) administration of trastuzumab: future prospectives.

Facts, views & vision in ObGyn

Papadmitriou K, Trinh XB, Altintas S, Van Dam PA, Huizing MT, Tjalma WA.
PMID: 26977267
Facts Views Vis Obgyn. 2015;7(3):176-80.

Trastuzumab was the first targeted therapy for HER2 positive breast cancer. It has become the standard of care for HER2 positive metastatic breast cancer since 2000 and in the adjuvant setting since 2006. Adjuvant it is given for a...

Cite
Papadmitriou K, Trinh XB, Altintas S, et al. The socio-economical impact of intravenous (IV) versus subcutaneous (SC) administration of trastuzumab: future prospectives. Facts Views Vis Obgyn. 2015;7(3):176-80
Papadmitriou, K., Trinh, X. B., Altintas, S., Van Dam, P. A., Huizing, M. T., & Tjalma, W. A. (2015). The socio-economical impact of intravenous (IV) versus subcutaneous (SC) administration of trastuzumab: future prospectives. Facts, views & vision in ObGyn, 7(3), 176-80.
Papadmitriou, K, et al. "The socio-economical impact of intravenous (IV) versus subcutaneous (SC) administration of trastuzumab: future prospectives." Facts, views & vision in ObGyn vol. 7,3 (2015): 176-80.
Papadmitriou K, Trinh XB, Altintas S, Van Dam PA, Huizing MT, Tjalma WA. The socio-economical impact of intravenous (IV) versus subcutaneous (SC) administration of trastuzumab: future prospectives. Facts Views Vis Obgyn. 2015;7(3):176-80. PMID: 26977267; PMCID: PMC4788333.
Copy Download .nbib Format: NLM
Novel paradigm for immunotherapy of breast cancer by engaging prophylactic immunity against hepatitis B.

Clinical and translational medicine

Malecki M, Sabo C, Foorohar A, Tombokan X.
PMID: 27539579
Clin Transl Med. 2016 Dec;5(1):32. doi: 10.1186/s40169-016-0111-8. Epub 2016 Aug 18.

BACKGROUND: Immunotherapy of patients suffering from the human epidermal growth factor receptor 2 overexpressing (HER-2(+)) breast cancers with the anti-HER-2 antibodies results in increase of the patients' overall survival. However, no prophylactic vaccine is available against HER-2(+) breast cancers....

Cite
Malecki M, Sabo C, Foorohar A, et al. Novel paradigm for immunotherapy of breast cancer by engaging prophylactic immunity against hepatitis B. Clin Transl Med. 2016;5(1):32doi: 10.1186/s40169-016-0111-8.
Malecki, M., Sabo, C., Foorohar, A., & Tombokan, X. (2016). Novel paradigm for immunotherapy of breast cancer by engaging prophylactic immunity against hepatitis B. Clinical and translational medicine, 5(1), 32. https://doi.org/10.1186/s40169-016-0111-8
Malecki, Marek, et al. "Novel paradigm for immunotherapy of breast cancer by engaging prophylactic immunity against hepatitis B." Clinical and translational medicine vol. 5,1 (2016): 32. doi: https://doi.org/10.1186/s40169-016-0111-8
Malecki M, Sabo C, Foorohar A, Tombokan X. Novel paradigm for immunotherapy of breast cancer by engaging prophylactic immunity against hepatitis B. Clin Transl Med. 2016 Dec;5(1):32. doi: 10.1186/s40169-016-0111-8. Epub 2016 Aug 18. PMID: 27539579; PMCID: PMC4990520.
Copy Download .nbib Format: NLM
Drug-screening and genomic analyses of HER2-positive breast cancer cell lines reveal predictors for treatment response.

Breast cancer (Dove Medical Press)

Jernström S, Hongisto V, Leivonen SK, Due EU, Tadele DS, Edgren H, Kallioniemi O, Perälä M, Mælandsmo GM, Sahlberg KK.
PMID: 28356768
Breast Cancer (Dove Med Press). 2017 Mar 21;9:185-198. doi: 10.2147/BCTT.S115600. eCollection 2017.

BACKGROUND: Approximately 15%-20% of all diagnosed breast cancers are characterized by amplified and overexpressed HER2 (= ErbB2). These breast cancers are aggressive and have a poor prognosis. Although improvements in treatment have been achieved after the introduction of trastuzumab...

Cite
Jernström S, Hongisto V, Leivonen SK, et al. Drug-screening and genomic analyses of HER2-positive breast cancer cell lines reveal predictors for treatment response. Breast Cancer (Dove Med Press). 2017;9:185-198doi: 10.2147/BCTT.S115600.
Jernström, S., Hongisto, V., Leivonen, S. K., Due, E. U., Tadele, D. S., Edgren, H., Kallioniemi, O., Perälä, M., Mælandsmo, G. M., & Sahlberg, K. K. (2017). Drug-screening and genomic analyses of HER2-positive breast cancer cell lines reveal predictors for treatment response. Breast cancer (Dove Medical Press), 9185-198. https://doi.org/10.2147/BCTT.S115600
Jernström, Sandra, et al. "Drug-screening and genomic analyses of HER2-positive breast cancer cell lines reveal predictors for treatment response." Breast cancer (Dove Medical Press) vol. 9 (2017): 185-198. doi: https://doi.org/10.2147/BCTT.S115600
Jernström S, Hongisto V, Leivonen SK, Due EU, Tadele DS, Edgren H, Kallioniemi O, Perälä M, Mælandsmo GM, Sahlberg KK. Drug-screening and genomic analyses of HER2-positive breast cancer cell lines reveal predictors for treatment response. Breast Cancer (Dove Med Press). 2017 Mar 21;9:185-198. doi: 10.2147/BCTT.S115600. eCollection 2017. PMID: 28356768; PMCID: PMC5367762.
Copy Download .nbib Format: NLM
Prolonged Response and Restoration of Functional Independence with Bevacizumab plus Vinorelbine as Third-Line Treatment for Breast Cancer-Related Leptomeningeal Metastases.

Case reports in oncology

Le Rhun E, Taillibert S, Boulanger T, Zairi F, Bonneterre J, Chamberlain MC.
PMID: 25848355
Case Rep Oncol. 2015 Feb 12;8(1):72-7. doi: 10.1159/000375293. eCollection 2015.

BACKGROUND: Survival of patients with leptomeningeal metastases (LM) and impaired functional status is limited to several months, and rarely does neurological function improve with treatment.CASE REPORT: A 34-year-old female with hormone-negative and HER2-positive metastatic breast cancer was diagnosed with...

Cite
Le Rhun E, Taillibert S, Boulanger T, et al. Prolonged Response and Restoration of Functional Independence with Bevacizumab plus Vinorelbine as Third-Line Treatment for Breast Cancer-Related Leptomeningeal Metastases. Case Rep Oncol. 2015;8(1):72-7doi: 10.1159/000375293.
Le Rhun, E., Taillibert, S., Boulanger, T., Zairi, F., Bonneterre, J., & Chamberlain, M. C. (2015). Prolonged Response and Restoration of Functional Independence with Bevacizumab plus Vinorelbine as Third-Line Treatment for Breast Cancer-Related Leptomeningeal Metastases. Case reports in oncology, 8(1), 72-7. https://doi.org/10.1159/000375293
Le Rhun, Emilie, et al. "Prolonged Response and Restoration of Functional Independence with Bevacizumab plus Vinorelbine as Third-Line Treatment for Breast Cancer-Related Leptomeningeal Metastases." Case reports in oncology vol. 8,1 (2015): 72-7. doi: https://doi.org/10.1159/000375293
Le Rhun E, Taillibert S, Boulanger T, Zairi F, Bonneterre J, Chamberlain MC. Prolonged Response and Restoration of Functional Independence with Bevacizumab plus Vinorelbine as Third-Line Treatment for Breast Cancer-Related Leptomeningeal Metastases. Case Rep Oncol. 2015 Feb 12;8(1):72-7. doi: 10.1159/000375293. eCollection 2015. PMID: 25848355; PMCID: PMC4361905.
Copy Download .nbib Format: NLM
Association of hospital and physician case volumes with cardiac monitoring and cardiotoxicity during adjuvant trastuzumab treatment for breast cancer: a retrospective cohort study.

CMAJ open

Chin-Yee NJ, Yan AT, Kumachev A, Ko D, Earle C, Tomlinson G, Trudeau ME, Krahn M, Krzyzanowska M, Pal R, Brezden-Masley C, Gavura S, Lien K, Chan K.
PMID: 27280116
CMAJ Open. 2016 Feb 18;4(1):E66-72. doi: 10.9778/cmajo.20150033. eCollection 2016.

BACKGROUND: Adjuvant trastuzumab is the standard of care for patients with HER2 overexpressing breast cancer, but use of trastuzumab may lead to cardiotoxicity. Our goal was to evaluate the relationship between hospital and physician case volume and cardiac outcomes...

Cite
Chin-Yee NJ, Yan AT, Kumachev A, et al. Association of hospital and physician case volumes with cardiac monitoring and cardiotoxicity during adjuvant trastuzumab treatment for breast cancer: a retrospective cohort study. CMAJ Open. 2016;4(1):E66-72doi: 10.9778/cmajo.20150033.
Chin-Yee, N. J., Yan, A. T., Kumachev, A., Ko, D., Earle, C., Tomlinson, G., Trudeau, M. E., Krahn, M., Krzyzanowska, M., Pal, R., Brezden-Masley, C., Gavura, S., Lien, K., & Chan, K. (2016). Association of hospital and physician case volumes with cardiac monitoring and cardiotoxicity during adjuvant trastuzumab treatment for breast cancer: a retrospective cohort study. CMAJ open, 4(1), E66-72. https://doi.org/10.9778/cmajo.20150033
Chin-Yee, Nicolas J, et al. "Association of hospital and physician case volumes with cardiac monitoring and cardiotoxicity during adjuvant trastuzumab treatment for breast cancer: a retrospective cohort study." CMAJ open vol. 4,1 (2016): E66-72. doi: https://doi.org/10.9778/cmajo.20150033
Chin-Yee NJ, Yan AT, Kumachev A, Ko D, Earle C, Tomlinson G, Trudeau ME, Krahn M, Krzyzanowska M, Pal R, Brezden-Masley C, Gavura S, Lien K, Chan K. Association of hospital and physician case volumes with cardiac monitoring and cardiotoxicity during adjuvant trastuzumab treatment for breast cancer: a retrospective cohort study. CMAJ Open. 2016 Feb 18;4(1):E66-72. doi: 10.9778/cmajo.20150033. eCollection 2016. PMID: 27280116; PMCID: PMC4866921.
Copy Download .nbib Format: NLM
Development of a peptide by phage display for SPECT imaging of resistance-susceptible breast cancer.

American journal of nuclear medicine and molecular imaging

Larimer BM, Deutscher SL.
PMID: 25143862
Am J Nucl Med Mol Imaging. 2014 Aug 15;4(5):435-47. eCollection 2014.

Personalized medicine is at the forefront of cancer diagnosis and therapy. Molecularly targeted therapies such as trastuzumab and tamoxifen have enhanced prognosis of patients with cancers expressing ERBB2 and the estrogen receptor, respectively. One obstacle to targeted therapy is...

Cite
Larimer BM, Deutscher SL. Development of a peptide by phage display for SPECT imaging of resistance-susceptible breast cancer. Am J Nucl Med Mol Imaging. 2014;4(5):435-47
Larimer, B. M., & Deutscher, S. L. (2014). Development of a peptide by phage display for SPECT imaging of resistance-susceptible breast cancer. American journal of nuclear medicine and molecular imaging, 4(5), 435-47.
Larimer, Benjamin M, and Deutscher, Susan L. "Development of a peptide by phage display for SPECT imaging of resistance-susceptible breast cancer." American journal of nuclear medicine and molecular imaging vol. 4,5 (2014): 435-47.
Larimer BM, Deutscher SL. Development of a peptide by phage display for SPECT imaging of resistance-susceptible breast cancer. Am J Nucl Med Mol Imaging. 2014 Aug 15;4(5):435-47. eCollection 2014. PMID: 25143862; PMCID: PMC4138138.
Copy Download .nbib Format: NLM
Higher locoregional recurrence rate for triple-negative breast cancer following neoadjuvant chemotherapy, surgery and radiotherapy.

SpringerPlus

Zhang C, Wang S, Israel HP, Yan SX, Horowitz DP, Crockford S, Gidea-Addeo D, Clifford Chao KS, Kalinsky K, Connolly EP.
PMID: 26240784
Springerplus. 2015 Jul 30;4:386. doi: 10.1186/s40064-015-1116-2. eCollection 2015.

BACKGROUND: Breast cancer subtype, determined by expression of estrogen/progesterone receptor (ER/PR) and human epidermal growth factor receptor (HER)-2, is predictive for prognosis. The importance of subtype to locoregional recurrence (LRR) following neoadjuvant chemotherapy (NAC) is unknown, particularly after adjuvant...

Cite
Zhang C, Wang S, Israel HP, et al. Higher locoregional recurrence rate for triple-negative breast cancer following neoadjuvant chemotherapy, surgery and radiotherapy. Springerplus. 2015;4:386doi: 10.1186/s40064-015-1116-2.
Zhang, C., Wang, S., Israel, H. P., Yan, S. X., Horowitz, D. P., Crockford, S., Gidea-Addeo, D., Clifford Chao, K. S., Kalinsky, K., & Connolly, E. P. (2015). Higher locoregional recurrence rate for triple-negative breast cancer following neoadjuvant chemotherapy, surgery and radiotherapy. SpringerPlus, 4386. https://doi.org/10.1186/s40064-015-1116-2
Zhang, Chi, et al. "Higher locoregional recurrence rate for triple-negative breast cancer following neoadjuvant chemotherapy, surgery and radiotherapy." SpringerPlus vol. 4 (2015): 386. doi: https://doi.org/10.1186/s40064-015-1116-2
Zhang C, Wang S, Israel HP, Yan SX, Horowitz DP, Crockford S, Gidea-Addeo D, Clifford Chao KS, Kalinsky K, Connolly EP. Higher locoregional recurrence rate for triple-negative breast cancer following neoadjuvant chemotherapy, surgery and radiotherapy. Springerplus. 2015 Jul 30;4:386. doi: 10.1186/s40064-015-1116-2. eCollection 2015. PMID: 26240784; PMCID: PMC4519490.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 2109 entries